Moreover, hepatocyte‐specific genetic deletion of ATX resulted in abrogated liver damage, inflammation and diminished fibrosis, and deregulated fatty acid metabolism, thereby attenuating HCC development suggesting ATX as an attractive drug candidate in liver fibrosis and cancer (Kaffe et al, 2017). Here, ENPP2 is linked to hepatocellular carcinoma.